These exciting preclinical observations necessitate the further consideration of combined GLP-1 and CCK1 receptor activation as a potential treatment option for the increasing numbers of people living with obesity and related diabetes. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.